checkAd

     247  0 Kommentare OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico - Seite 3

    OncBioMune Pharmaceuticals, prostate cancer vaccine, ProscaVax, patent, intellectual property, prostate cancer vaccine, cancer vaccines, OBMP stock, OBMP investor relations, OBMP news, OncBioMune Mexico

    Lesen Sie auch

    Contact:
    OncBioMune Pharmaceuticals, Inc.
    Andrew Kucharchuk
    President and Chief Financial Officer
    akucharchuk@oncbiomune.com


    Seite 3 von 3
    Verfasst von Marketwired
    OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico - Seite 3 BATON ROUGE, LA--(Marketwired - June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer …